TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Currently, the arise of drug resistance and undesirable off-target effects of anti-cancer
agents are major challenges for cancer treatment, which energizes medicinal chemists to …

Simple Summary Beyond mutations, epigenetic changes have been described as drivers for
cancer as well. While leaving the overall DNA structure intact, they can be responsible for …

Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing
histone deacetylation. Aberrant expression of HDACs is associated with various human …

This review classifies drug‐design strategies successfully implemented in the development
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …

Targeted protein degradation refers to the use of small molecules that recruit a ubiquitin
ligase to a target protein for ubiquitination and subsequent proteasome-dependent …

Histone deacetylases (HDACs) play an important role in regulating the expression of genes
involved in tumorigenesis and tumor maintenance, and hence they have been considered …

Since the approval of three hydroxamic acid-based HDAC inhibitors as anticancer drugs,
such functional groups acquired even more notoriety in synthetic medicinal chemistry. The …

The acetylation of histone and non-histone proteins has been implicated in several disease
states. Modulation of such epigenetic modifications has therefore made histone …